Compounders Research Compare

Shattuck Labs, Inc.(STTK)

Biotechnology · Austin, TX

$5.86-0.64 (-9.85%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Shattuck Labs, Inc.

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Austin, TX

40 employees

www.shattucklabs.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Taylor H. Schreiber

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T20:33:07.117Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:33:07.117Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 529,582,205
TTM free cash flow · period ending 2026-06-30: -41,240,000

FMP input reference: 35a271d61501d442ff1d5238fcf80e89d6bdfa5e87b371fe53e06a7cba571f48

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

STTK Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

STTK Competitors' Price/FCF Ratio

Shattuck Labs, Inc.

Current

Market Cap

$529.58M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nuvectis Pharma, Inc.

Market Cap

$531.52M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$531.98M

Price/FCF Ratio

30.39

TTM Avg

34.94

3Y Avg

46.00

5Y Avg

46.00

Monopar Therapeutics Inc.

Market Cap

$533.04M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$524.43M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ProKidney Corp.

Market Cap

$538.01M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$519.25M

Price/FCF Ratio

N/A

TTM Avg

0.26

3Y Avg

0.26

5Y Avg

0.26

Aclaris Therapeutics, Inc.

Market Cap

$516.76M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$548.51M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

908 Devices Inc.

Market Cap

$505.87M

Price/FCF Ratio

1049.51

TTM Avg

838.04

3Y Avg

838.04

5Y Avg

838.04

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Shattuck Labs, Inc. (STTK)	$529.58M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$531.52M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$531.98M	30.39	34.94	46.00	46.00
Monopar Therapeutics Inc. (MNPR)vs ›	$533.04M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$524.43M	N/A	N/A	N/A	N/A
ProKidney Corp. (PROK)vs ›	$538.01M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	0.26	0.26	0.26
Aclaris Therapeutics, Inc. (ACRS)vs ›	$516.76M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$548.51M	N/A	N/A	N/A	N/A
908 Devices Inc. (MASS)vs ›	$505.87M	1049.51	838.04	838.04	838.04

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics